FDC Peer Comparison

NSE: FDC | BSE: 531599

₹342.50

₹-1.35 (-0.39%)

As on 28-Aug-2026IST

Market cap

₹5,570 Cr

Revenue (TTM)

₹2,190 Cr

P/E Ratio

P/B Ratio

2.1

Div. Yield

0 %

Edit

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	5,570	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	2,190	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	292.56	735.15	678.07	666.92	169.62
Net Margin (%)	12.56	26.88	28.10	20.60	6.90
RoE (%)	12.56	19.16	19.73	18.75	20.76
Price to Earnings	19.04	29.25	28.74	28.35	104.74
Price-To-Book	2.13	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	2,190.22	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	2,329.19	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	1,854.76	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	335.46	941.63	796.58	1,139.61	229.86
Depreciation	59.47	57.58	78.10	281.06	17.24
EBIT	275.99	884.05	718.48	858.55	212.62
Interest	4.65	7.69	0.88	190.64	5.72
Other Income	138.97	165.62	125.96	7.45	26.48
Exceptional Items	-20.79	-49.16	0.00	-17.24	-5.13
Profit before Tax	389.52	992.82	843.56	658.12	228.25
Provision for Tax	96.96	257.67	165.49	-8.80	58.63
Profit after Tax	292.56	735.15	678.07	666.92	169.62

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	2,485.11	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	69.78	91.50	28.74	1,392.75	134.50
Current Liabilities	364.08	627.48	385.94	2,077.10	981.81
Total Liabilities	3,643.30	4,911.11	3,207.85	6,862.28	1,879.19

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	1,628.07	770.28	1,291.22	5,617.77	42.47
Current Assets	1,132.52	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	3,643.30	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	0.11	2.50	0.55	2,421.66	0.00
Net Current Assets	768.45	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	107.54	363.79	0.64	64.29	98.41

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	317.57	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-199.51	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-92.12	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	25.94	383.07	59.32	103.72	30.57

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	16.52	26.21	26.22	13.59	21.29
ROE (%)	12.56	19.16	19.73	18.75	20.76
ROA (%)	10.39	14.95	18.69	9.26	9.67
EBIT Margin (%)	12.60	34.40	31.41	26.58	8.74
Net Margin (%)	12.56	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	3.40	10.69	15.01	9.59	31.10
EBIT Growth (%)	8.85	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	8.72	-9.09	19.61	62.68	-7.49
EPS Growth (%)	14.73	14.40	17.73	67.41	-18.33
Book Value Growth (%)	8.77	17.30	23.77	10.19	7.70

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	18.04	27.87	28.74	27.66	102.37
Price / Book Value	2.13	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.00	1.60	0.16	0.55	0.51
EV/EBITDA	15.00	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	6,419.65	18,318.10	15,219.80	19,292.77	21,515.93

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.00	0.00	0.00	0.24	0.00
Short term debt to equity ratio	--	0.00	0.00	0.14	--
Current Ratio	3.11	6.06	6.70	0.74	1.77
Quick Ratio	2.13	5.31	5.59	0.53	0.73
Interest Coverage	84.79	130.11	959.59	4.45	40.90

	FDC	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	6.93	7.07	36.10	21.07	8.79
Asset Turnover	0.78	0.52	0.63	0.45	1.39
Receivable days	18.98	29.10	110.70	54.07	35.81
Inventory Days	64.09	69.53	65.86	32.16	82.25
Payable days	96.96	76.77	105.88	140.91	124.39
Cash Conversion Cycle	-13.89	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.